photobyphm / Shutterstock.com
6 November 2019AmericasRory O'Neill
Pfizer and Sun settle Bosulif dispute
Pfizer and Indian drugmaker Sun Pharmaceuticals have agreed to settle patent litigation over a generic version of Pfizer’s leukaemia drug, Bosulif.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
8 April 2019 India-based drugmaker Sun Pharma has accused Pfizer of infringing a patent with a new extended-release formulation of Lyrica.
Big Pharma
17 December 2019 A subsidiary of Pfizer, Hospira, infringed one of Amgen’s patents and must pay damages of $70 million, the US Court of Appeal for the Federal Circuit has affirmed.
Editor's picks
Editor's picks
Americas
8 April 2019 India-based drugmaker Sun Pharma has accused Pfizer of infringing a patent with a new extended-release formulation of Lyrica.
Big Pharma
17 December 2019 A subsidiary of Pfizer, Hospira, infringed one of Amgen’s patents and must pay damages of $70 million, the US Court of Appeal for the Federal Circuit has affirmed.
Americas
8 April 2019 India-based drugmaker Sun Pharma has accused Pfizer of infringing a patent with a new extended-release formulation of Lyrica.
Big Pharma
17 December 2019 A subsidiary of Pfizer, Hospira, infringed one of Amgen’s patents and must pay damages of $70 million, the US Court of Appeal for the Federal Circuit has affirmed.